Compare D R Horton Inc (DHI) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Johnson & Johnson — how do they compare? D R Horton Inc trades at $134.3 (market cap $37.99B), while Johnson & Johnson trades at $260.72 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 16.3× D R Horton Inc's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Johnson & Johnson for 129 Days on average.
| DHI | JNJ | |
|---|---|---|
Market Cap | $37.99B | $618.09B |
Volume | 2,974,460 | 6,050,983 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $278.43 |
52-Week Low | $132.53 | $186.00 |
Typical Hold Time | 46 Days | 129 Days |
Enterprise Value | $43.09B | $646.37B |
Dividend Yield | 1.33% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $134.49, down 0.91% on the day amid broader housing sector weakness. The stock shows bearish technical signals with resistance at $137 and support at $133. Fundamentally, the company maintains solid profitability with 9.15% net margin and 12.75% ROE, though revenue declined to $34.25B in 2025. Recent earnings beats and a $0.45 dividend declaration provide some positive catalysts despite macroeconomic headwinds affecting homebuilders.
DHI presents a mixed outlook with attractive valuation (P/E 12.95) and strong analyst support (47% buy ratings, $156.57 target) offset by housing market risks. Rising mortgage rates and inflation concerns create near-term pressure, but the company's consistent earnings performance and buyback capacity offer long-term value. Investors should weigh the discounted valuation against sector-specific macroeconomic challenges.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
